Keros Therapeutics, Inc.
KROS
$10.94
-$0.40-3.53%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -222.27% | 76.28% | -120.68% | 422.54% | 13.09% |
| Total Depreciation and Amortization | 1.27% | 6.76% | 7.56% | 3.61% | 5.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 72.54% | -49.63% | -3.43% | -3.33% | 4.18% |
| Change in Net Operating Assets | -319.52% | 165.78% | -387.47% | 129.04% | -179.03% |
| Cash from Operations | -940.01% | 110.97% | -118.38% | 450.31% | -50.85% |
| Capital Expenditure | -1.52% | 81.67% | -27.43% | -95.50% | 25.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1.52% | 81.67% | -27.43% | -95.50% | 25.13% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -9.29% | 723.53% | 325.00% | -99.99% | -51.60% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -270,550.71% | 723.53% | 325.00% | -99.99% | -51.56% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -12,567.21% | 110.74% | -118.88% | 449.15% | -76.61% |